XSHE
000004
Market cap217mUSD
Dec 05, Last price
11.60CNY
1D
1.58%
1Q
11.86%
Jan 2017
-74.16%
Name
Shenzhen Cau Technology Co.
Chart & Performance
P/E
—
P/S
15.56
EPS
—
Div Yield, %
—
Shrs. gr., 5y
9.53%
Rev. gr., 5y
-1.84%
Revenues
99m
-10.35%
Net income
-132m
CFO
-17m
L-53.75%
Dividend
Jun 19, 20030.024 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Shenzhen GuoHua Network Security Technology Co., Ltd., together with its subsidiaries, researches, develops, manufactures, and sells bio-pharmaceutical products in China. It offers products in the areas of cardiovascular, anti-infective, tumor immunity, nerve/analgesic, API, and gastrointestinal/reproductive. The company also provides clindamycin phosphate, adenosine triphosphate magnesium chloride, diisopropylamine dichloroacetate, cyclophosphamide, cytidine triphosphate disodium, urokinase, and other injection products. In addition, it engages in the development and sale of real estate properties, as well as housing property management activities. The company was formerly known as Shenzhen Cau Technology Co., Ltd and changed its name to Shenzhen GuoHua Network Security Technology Co., Ltd. in November 2020. Shenzhen GuoHua Network Security Technology Co., Ltd., was founded in 1990 and is based in Shenzhen, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||